Skip to main content

Table 1 Background Information of Childhood Cancer Survivors

From: Surveillance cardiopulmonary exercise testing can risk-stratify childhood cancer survivors: underlying pathophysiology of poor exercise performance and possible room for improvement

 

Male

Female

PmaxVO2

Normal (≥ 80%)

Poor (< 80%)

p value

Normal (≥ 80%)

Poor (< 80%)

p value

Number

20

18

 

18

22

 

Age at Diagnosis (years)

7.1 ± 4.4

9.1 ± 5.4

0.24

4 ± 2.9

7.3 ± 4.8

0.018

Years after Diagnosis

6.8 ± 3.8

6.3 ± 4.2

0.75

10.3 ± 3.7

7.8 ± 5.0

0.09

Diagnosis

      

Leukemia

8 (40%)

11 (61%)

0.79

6 (33%)

6 (27%)

0.91

ALL

5

8

 

5

5

 

AML

1

0

 

0

1

 

Post-HSCT

2

3

 

1

0

 

Lymphoma

8 (40%)

4 (22%)

0.70

0 (0%)

6 (27%)

0.60

Hodgkin

3

1

 

0

5

 

Non-Hodgkin

5

3

 

0

1

 

Solid Tumor

4 (20%)

3 (17%)

0.94

12 (67%)

10 (46%)

0.76

Wilms’ tumor

1

0

 

3

5

 

Osteosarcoma

0

1

 

0

2

 

Ewing sarcoma

0

0

 

3

1

 

Neuroblastoma

0

1

 

4

1

 

Other

3

1

 

2

1

 

Treatment

      

Anthracycline (mg/m2)

183 ± 102

164 ± 90

0.57

219 ± 122

218 ± 112

0.98

Chest RT

1 (5%)

3 (2%)

0.32

7 (39%)

9 (41%)

0.62

≥ 15 Gy

0

1

 

5

6

 

< 15 Gy

1

2

 

2

3

 

Echocardiogram

      

LVSF (%)

35.0 ± 4.6

34.7 ± 3.0

0.86

33.8 ± 3.8

34.7 ± 2.4

0.34

LVEF (%)

63.6 ± 4.9

61.5 ± 4.5

0.21

58.7 ± 3.9

61.3 ± 3.5

0.05

  1. %pmaxVO2: %predicted maximum oxygen consumption, ALL: acute lymphoblastic leukemia, AML: acute myeloblastic leukemia, Post-HSCT: post hematopoietic cell transplant, RT: radiation therapy, LVSF: left ventricular shortening fraction, LVEF: left ventricular ejection fraction
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us